Skip to content

Study · Randomized controlled trial · n = 92 · 2018

3 results

Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial.

Besch G, Perrotti A, Salomon du Mont L, Puyraveau M, Ben-Said X, Baltres M, Barrucand B, Flicoteaux G, Vettoretti L, Samain E, Chocron S, Pili-Floury S

Cardiovascular diabetology1 Nov 2018Cited by 24 (Europe PMC)

PMID30384842 (opens in a new tab)PMCIDPMC6211400 (opens in a new tab)DOI10.1186/s12933-018-0784-y (opens in a new tab)PepBankPUB-30384842
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

BackgroundThe aim of the study was to investigate whether intravenous (iv) infusion of exenatide, a synthetic GLP-1 receptor agonist, could provide a protective effect against myocardial ischemia-reperfusion injury after coronary artery bypass graft (CABG) surgery.MethodsA sub study analysis of patients > 18 years admitted for elective CABG and included in the ExSTRESS trial was conducted. Patients were randomized to receive either iv exenatide (1-h bolus of 0.05 µg min-1 followed by a constant infusion of 0.025 µg min-1) (exenatide group) or iv insulin therapy (control group) for blood glucose control (target range 100-139 mg dl-1) during the first 48 h after surgical incision. All serum levels of troponin I measured during routine care in the Cardiac Surgery ICU were recorded. The primary outcome was the highest value of plasma concentration of troponin I measured between 12 and 24 h after ICU admission. The proportion of patients presenting an echocardiographic left ventricular ejection fraction (LVEF) > 50% at the follow-up consultation was compared between the two groups.ResultsFinally, 43 and 49 patients were analyzed in the control and exenatide groups, respectively {age: 69 [61-76] versus 71 [63-75] years; baseline LVEF < 50%: 6 (14%) versus 16 (32%) patients; on-pump surgery: 29 (67%) versus 33 (67%) patients}. The primary outcome did not significantly differ between the two groups (3.34 [1.06-6.19] µg l-1 versus 2.64 [1.29-3.85] µg l-1 in the control and exenatide groups, respectively; mean difference (MD) [95% confidence interval (95% CI)] 0.16 [- 0.25; 0.57], p = 0.54). The highest troponin value measured during the first 72 h in the ICU was 6.34 [1.36-10.90] versus 5.04 [2.39-7.18] µg l-1, in the control and exenatide groups respectively (MD [95% CI] 0.20 [- 0.22; 0.61], p = 0.39). At the follow-up consultation, 5 (12%) versus 8 (16%) patients presented a LVEF < 50% in the control and in the exenatide groups respectively (relative risk [95% CI] 0.68 [0.16; 2.59], p = 0.56).ConclusionsPostoperative iv exenatide did not provide any additional cardioprotective effect compared to iv insulin in low-risk patients undergoing scheduled CABG surgery. Trial registration ClinicalTrials.gov Identifier NCT01969149, date of registration: January 7th, 2015; EudraCT No. 2009-009254-25 A, date of registration: January 6th, 2009.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults undergoing CABG, intravenous exenatide did not significantly change peak troponin I at 12-24 h versus intravenous insulin.

    In plain wordsIn adults undergoing CABG, exenatide did not significantly change peak troponin I at 12-24 h compared with insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePeak troponin I at 12-24 h
    Study

    n = 92

    Comparator
    intravenous insulin
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1-h bolus of 0.05 µg/min followed by 0.025 µg/min infusion · intravenous · first 48 h after surgical incisionAs given in this study (human).

    Measurements

    Peak troponin I
    2.64 µg/l
    exenatide
    Peak troponin I
    3.34 µg/l
    insulin
    Mean difference in peak troponin I
    0.16 µg/l
    control versus exenatide, 95% CI -0.25 to 0.57

    Source sentences

    Summary
    The primary outcome did not significantly differ between the two groups (3.34 [1.06-6.19] µg l-1 versus 2.64 [1.29-3.85] µg l-1 in the control and exenatide groups, respectively; mean difference (MD) [95% confidence interval (95% CI)] 0.16 [- 0.25; 0.57], p = 0.54).
    2 context sentences
    Summary · context
    A sub study analysis of patients > 18 years admitted for elective CABG and included in the ExSTRESS trial was conducted.
    Summary · context
    Finally, 43 and 49 patients were analyzed in the control and exenatide groups, respectively {age: 69 [61-76] versus 71 [63-75] years; baseline LVEF < 50%: 6 (14%) versus 16 (32%) patients; on-pump surgery: 29 (67%) versus 33 (67%) patients}.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults undergoing CABG, intravenous exenatide did not significantly change peak troponin during the first 72 h versus intravenous insulin.

    In plain wordsIn adults undergoing CABG, exenatide did not significantly change peak troponin during the first 72 h compared with insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePeak troponin during first 72 h
    Study

    n = 92

    Comparator
    intravenous insulin
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1-h bolus of 0.05 µg/min followed by 0.025 µg/min infusion · intravenous · first 48 h after surgical incisionAs given in this study (human).

    Measurements

    Peak troponin
    5.04 µg/l
    exenatide
    Peak troponin
    6.34 µg/l
    insulin
    Mean difference in peak troponin
    0.2 µg/l
    control versus exenatide, 95% CI -0.22 to 0.61

    Source sentences

    Summary
    The highest troponin value measured during the first 72 h in the ICU was 6.34 [1.36-10.90] versus 5.04 [2.39-7.18] µg l-1, in the control and exenatide groups respectively (MD [95% CI] 0.20 [- 0.22; 0.61], p = 0.39).
    2 context sentences
    Summary · context
    A sub study analysis of patients > 18 years admitted for elective CABG and included in the ExSTRESS trial was conducted.
    Summary · context
    Finally, 43 and 49 patients were analyzed in the control and exenatide groups, respectively {age: 69 [61-76] versus 71 [63-75] years; baseline LVEF < 50%: 6 (14%) versus 16 (32%) patients; on-pump surgery: 29 (67%) versus 33 (67%) patients}.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults undergoing CABG, the proportion with LVEF below 50% at follow-up did not differ significantly between exenatide and insulin.

    In plain wordsIn adults undergoing CABG, low heart ejection fraction at follow-up did not differ significantly between exenatide and insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeLVEF below 50% at follow-up
    Study

    n: not reported in source

    Comparator
    intravenous insulin
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1-h bolus of 0.05 µg/min followed by 0.025 µg/min infusion · intravenous · first 48 h after surgical incisionAs given in this study (human).

    Measurements

    LVEF below 50%
    16%
    exenatide
    LVEF below 50%
    12%
    insulin
    Relative risk of LVEF below 50%
    0.68 ratio
    exenatide versus control, 95% CI 0.16 to 2.59

    Source sentences

    Summary
    At the follow-up consultation, 5 (12%) versus 8 (16%) patients presented a LVEF < 50% in the control and in the exenatide groups respectively (relative risk [95% CI] 0.68 [0.16; 2.59], p = 0.56).
    2 context sentences
    Summary · context
    A sub study analysis of patients > 18 years admitted for elective CABG and included in the ExSTRESS trial was conducted.
    Summary · context
    Finally, 43 and 49 patients were analyzed in the control and exenatide groups, respectively {age: 69 [61-76] versus 71 [63-75] years; baseline LVEF < 50%: 6 (14%) versus 16 (32%) patients; on-pump surgery: 29 (67%) versus 33 (67%) patients}.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2/3NCT01969149

Exenatide for Stress Hyperglycemia

Centre Hospitalier Universitaire de Besanconn = 110Jan 2015 to Dec 2016

Stress Hyperglycemia

Trial pageClinicalTrials.govUpdated 6 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.